TG Therapeutics Inc (TGTX)
17.13
-0.04
(-0.23%)
USD |
NASDAQ |
May 08, 16:00
17.08
-0.05
(-0.29%)
After-Hours: 20:00
TG Therapeutics Enterprise Value: 2.444B for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | 2.444B |
| May 06, 2024 | 2.342B |
| May 03, 2024 | 2.292B |
| May 02, 2024 | 2.328B |
| May 01, 2024 | 2.244B |
| April 30, 2024 | 1.901B |
| April 29, 2024 | 1.849B |
| April 26, 2024 | 1.872B |
| April 25, 2024 | 1.940B |
| April 24, 2024 | 1.951B |
| April 23, 2024 | 1.992B |
| April 22, 2024 | 1.969B |
| April 19, 2024 | 1.920B |
| April 18, 2024 | 1.952B |
| April 17, 2024 | 1.926B |
| April 16, 2024 | 1.954B |
| April 15, 2024 | 1.965B |
| April 12, 2024 | 1.979B |
| April 11, 2024 | 2.072B |
| April 10, 2024 | 2.064B |
| April 09, 2024 | 2.124B |
| April 08, 2024 | 2.104B |
| April 05, 2024 | 2.035B |
| April 04, 2024 | 2.025B |
| April 03, 2024 | 2.027B |
| Date | Value |
|---|---|
| April 02, 2024 | 2.022B |
| April 01, 2024 | 2.073B |
| March 31, 2024 | 2.141B |
| March 28, 2024 | 2.231B |
| March 27, 2024 | 2.287B |
| March 26, 2024 | 2.267B |
| March 25, 2024 | 2.305B |
| March 22, 2024 | 2.275B |
| March 21, 2024 | 2.238B |
| March 20, 2024 | 2.256B |
| March 19, 2024 | 2.250B |
| March 18, 2024 | 2.207B |
| March 15, 2024 | 2.233B |
| March 14, 2024 | 2.255B |
| March 13, 2024 | 2.312B |
| March 12, 2024 | 2.329B |
| March 11, 2024 | 2.410B |
| March 08, 2024 | 2.474B |
| March 07, 2024 | 2.662B |
| March 06, 2024 | 2.698B |
| March 05, 2024 | 2.675B |
| March 04, 2024 | 2.642B |
| March 01, 2024 | 2.656B |
| February 29, 2024 | 2.542B |
| February 28, 2024 | 2.605B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
374.24M
Minimum
Jun 16 2022
7.393B
Maximum
Dec 21 2020
2.345B
Average
2.025B
Median
Apr 04 2024
Enterprise Value Benchmarks
| Amicus Therapeutics Inc | 3.177B |
| Geron Corp | 1.929B |
| Editas Medicine Inc | 141.59M |
| G1 Therapeutics Inc | 199.84M |
| Mersana Therapeutics Inc | 247.47M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.71M |
| Revenue (Quarterly) | 63.47M |
| Total Expenses (Quarterly) | 72.74M |
| EPS Diluted (Quarterly) | -0.07 |
| Gross Profit Margin (Quarterly) | 91.43% |
| Profit Margin (Quarterly) | -16.87% |
| Earnings Yield | 1.28% |
| Operating Earnings Yield | 1.88% |
| Normalized Earnings Yield | 1.284 |